Motixafortide: Side Effects
Known side effects, contraindications, and interactions
๐TL;DR
- โข5 known side effects documented
- โข3 mild, 1 moderate, 1 severe
- โข2 contraindications listed
Compare side effects across multiple peptides โ
Side Effects Severity Chart
Reported in approximately 50% of patients. Generally mild (Grade 1-2) and transient. Managed with acetaminophen premedication.
Redness at the injection site reported in approximately 27.5% of patients. Transient and self-limiting.
Itching at the injection site reported in approximately 21.3% of patients. Transient and self-limiting.
Flushing, generalized pruritus, and warmth have been reported. Managed with premedication (H1, H2 blockers, leukotriene inhibitor).
Anaphylactic shock and serious hypersensitivity reactions can occur. A boxed warning requires administration in settings equipped for immediate treatment of anaphylaxis.
โContraindications
- โขKnown hypersensitivity to motixafortide or any excipient
- โขPatients unable to receive required premedication
โ ๏ธDrug Interactions
- โขMotixafortide is used in combination with filgrastim (G-CSF), which is an integral part of the approved mobilization protocol.
- โขNo other drug interactions have been formally characterized per prescribing information.
Community-Reported Side Effects
See which side effects community members report most frequently.
0View community protocolsSafety Overview#
Motixafortide has an acceptable safety profile for its approved indication. The most common adverse events are injection site reactions, which are generally mild and transient. The primary safety concern is the risk of anaphylactic shock, which requires premedication and administration in an equipped healthcare setting.
Boxed Warning#
The APHEXDA prescribing information contains warnings for:
- Anaphylactic shock and hypersensitivity reactions: Can occur with motixafortide. Must be administered in a healthcare setting equipped to manage anaphylaxis.
- Premedication required: H1 blocker, H2 blocker, leukotriene inhibitor, and acetaminophen must be given before each dose.
Common Adverse Events#
From the GENESIS Phase 3 trial:
| Adverse Event | Motixafortide + G-CSF | Placebo + G-CSF |
|---|---|---|
| Any adverse event | 98.8% | 95.2% |
| Grade 3/4 adverse event | 68.8% | 42.9% |
| Injection site pain | ~50% | -- |
| Injection site erythema | ~27.5% | -- |
| Injection site pruritus | ~21.3% | -- |
Note: The majority of Grade 3/4 adverse events were cytopenias in the post-ASCT period prior to engraftment, which occur in both treatment arms and are expected consequences of the transplantation process rather than drug-specific toxicity.
Injection Site Reactions#
Injection site reactions are the most common motixafortide-specific adverse events:
- Pain: ~50% incidence, generally Grade 1-2
- Erythema: ~27.5% incidence, transient
- Pruritus: ~21.3% incidence, transient
- Managed with acetaminophen premedication
- Generally resolve within hours
Systemic Reactions#
Systemic allergic-type reactions including flushing, generalized pruritus, and warmth can occur. These are managed by the required premedication regimen:
| Premedication | Drug Class | Purpose |
|---|---|---|
| Diphenhydramine or similar | H1 blocker | Prevent histamine-mediated reactions |
| Famotidine or similar | H2 blocker | Prevent histamine-mediated reactions |
| Montelukast or similar | Leukotriene inhibitor | Prevent leukotriene-mediated reactions |
| Acetaminophen | Analgesic/antipyretic | Manage injection site pain |
Safety Comparison with Plerixafor#
| Parameter | Motixafortide | Plerixafor (Mozobil) |
|---|---|---|
| Injection site reactions | ~50% (pain) | ~34% |
| GI effects | Not prominent | Diarrhea 37%, nausea 34% |
| Anaphylaxis warning | Yes (boxed) | Yes (in labeling) |
| Premedication required | Yes (4 agents) | Not required |
| Administration setting | Healthcare facility | Healthcare facility |
Safety Profile Context#
Motixafortide belongs to the Immune category of research peptides. Understanding the side effect profile of Motixafortide is essential for researchers designing clinical protocols and for healthcare providers advising patients. The side effects documented here are based on available clinical trial data and may not represent the complete safety profile.
Reported Side Effects#
The following side effects have been documented in clinical studies of Motixafortide. Side effect severity and frequency are based on available clinical data.
Injection site pain#
Severity: mild | Frequency: common
Reported in approximately 50% of patients. Generally mild (Grade 1-2) and transient. Managed with acetaminophen premedication.
Injection site erythema#
Severity: mild | Frequency: common
Redness at the injection site reported in approximately 27.5% of patients. Transient and self-limiting.
Injection site pruritus#
Severity: mild | Frequency: common
Itching at the injection site reported in approximately 21.3% of patients. Transient and self-limiting.
Systemic allergic-type reactions#
Severity: moderate | Frequency: uncommon
Flushing, generalized pruritus, and warmth have been reported. Managed with premedication (H1, H2 blockers, leukotriene inhibitor).
Anaphylactic reactions#
Severity: severe | Frequency: rare
Anaphylactic shock and serious hypersensitivity reactions can occur. A boxed warning requires administration in settings equipped for immediate treatment of anaphylaxis.
Contraindications#
The following contraindications have been identified for Motixafortide based on available research and pharmacological considerations:
- Known hypersensitivity to motixafortide or any excipient
- Patients unable to receive required premedication
Individuals with any of these conditions should not use Motixafortide without consulting a qualified healthcare provider.
Drug Interactions#
The following potential drug interactions have been identified for Motixafortide:
- Motixafortide is used in combination with filgrastim (G-CSF), which is an integral part of the approved mobilization protocol.
- No other drug interactions have been formally characterized per prescribing information.
Drug interaction studies for Motixafortide remain limited. Researchers should exercise caution when combining Motixafortide with other compounds and consult relevant pharmacological references.
Related Reading#
Unlock full side effects analysis
Free access to detailed safety profiles and interaction guidance for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About Motixafortide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.